These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 6531784)

  • 21. Nuclear binding of the estrogen receptor: heterogeneity of sites and uterotropic response.
    Clark JH; Markaverich B; Upchurch S; Eriksson H; Hardin JW
    Adv Exp Med Biol; 1979; 117():17-46. PubMed ID: 474276
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of ATP on the regulation of the steroid binding activity of the oestradiol receptor.
    Lahooti H; Thorsen T; Aakvaag A
    J Steroid Biochem; 1990 Jul; 36(4):333-43. PubMed ID: 2168008
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Physical-chemical properties of the estrogen receptor solubilized by micrococcal nuclease.
    Geier A; Haimsohn M; Beery R; Lunenfeld B
    J Steroid Biochem; 1985 Aug; 23(2):137-43. PubMed ID: 4033115
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Properties of the estrogen receptor in the human oviduct and its interaction with ethinylestradiol and mestranol in vitro.
    Muechler EK; Kohler D
    J Clin Endocrinol Metab; 1980 Nov; 51(5):962-7. PubMed ID: 7419693
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Extensive in situ activation of nuclear estrogen receptors after exposure of murine uteri to [3H]estradiol or [3H]4-hydroxytamoxifen.
    Pavlik EJ; Nelson K; van Nagell JR; Donaldson ES; Walden ML; Gallion H; Kenady DE
    Endocrinology; 1987 Apr; 120(4):1608-14. PubMed ID: 3830064
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of estradiol concentration on levels of nuclear estrogen receptors in MCF-7 breast tumor cells.
    Umans RS; Weichselbaum RR; Johnson CM; Little JB
    J Steroid Biochem; 1984 Feb; 20(2):605-9. PubMed ID: 6708541
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Bioactivities, estrogen receptor interactions, and plasminogen activator-inducing activities of tamoxifen and hydroxy-tamoxifen isomers in MCF-7 human breast cancer cells.
    Katzenellenbogen BS; Norman MJ; Eckert RL; Peltz SW; Mangel WF
    Cancer Res; 1984 Jan; 44(1):112-9. PubMed ID: 6537799
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immunological differences between the estradiol-, tamoxifen- and 4-hydroxy-tamoxifen-estrogen receptor complexes detected by two monoclonal antibodies.
    Giambiagi N; Pasqualini JR
    J Steroid Biochem; 1988; 30(1-6):213-7. PubMed ID: 3386244
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Identification of immunoassayable estrogen receptor lacking hormone binding ability in tamoxifen-treated rat uterus.
    Nakao M; Sato B; Koga M; Noma K; Kishimoto S; Matsumoto K
    Biochem Biophys Res Commun; 1985 Oct; 132(1):336-42. PubMed ID: 3904747
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antiestrogenic potency and binding characteristics of the triphenylethylene H1285 in MCF-7 human breast cancer cells.
    Sheen YY; Ruh TS; Mangel WF; Katzenellenbogen BS
    Cancer Res; 1985 Sep; 45(9):4192-9. PubMed ID: 4040807
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Characterization of the subunit nature of nuclear estrogen receptors by chemical cross-linking and dense amino acid labeling.
    Miller MA; Mullick A; Greene GL; Katzenellenbogen BS
    Endocrinology; 1985 Aug; 117(2):515-22. PubMed ID: 4017945
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Interaction of the antiestrogen [3H]H1285 with the two forms of the molybdate-stabilized calf uterine estrogen receptor.
    Keene JL; Ruh MF; Ruh TS
    J Steroid Biochem; 1984 Dec; 21(6):625-31. PubMed ID: 6527530
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tamoxifen and 5-fluorouracil in breast cancer: cytotoxic synergism in vitro.
    Benz C; Cadman E; Gwin J; Wu T; Amara J; Eisenfeld A; Dannies P
    Cancer Res; 1983 Nov; 43(11):5298-303. PubMed ID: 6616464
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Estrogen receptor synthesis and turnover in MCF-7 breast cancer cells measured by a density shift technique.
    Eckert RL; Mullick A; Rorke EA; Katzenellenbogen BS
    Endocrinology; 1984 Feb; 114(2):629-37. PubMed ID: 6690295
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Monoclonal antibodies to human estrogen receptor.
    Greene GL; Nolan C; Engler JP; Jensen EV
    Proc Natl Acad Sci U S A; 1980 Sep; 77(9):5115-9. PubMed ID: 7001472
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Failure of estradiol immunofluorescence in MCF-7 breast cancer cells to detect estrogen receptors.
    Mercer WD; Edwards DP; Chamness GC; McGuire WL
    Cancer Res; 1981 Nov; 41(11 Pt 1):4644-52. PubMed ID: 7030480
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Isopycnic banding in metrizamide of the uterine cytosol and nuclear estradiol receptor.
    Baskevitch PP; Rochefort H
    Mol Cell Endocrinol; 1981 May; 22(2):195-210. PubMed ID: 7239002
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of the physicochemical properties of uterine nuclear estrogen receptors bound to estradiol or 4-hydroxytamoxifen.
    Attardi B; Happe HK
    Endocrinology; 1986 Aug; 119(2):904-15. PubMed ID: 3732150
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Various phosphorylation pathways, depending on agonist and antagonist binding to endogenous estrogen receptor alpha (ERalpha), differentially affect ERalpha extractability, proteasome-mediated stability, and transcriptional activity in human breast cancer cells.
    Marsaud V; Gougelet A; Maillard S; Renoir JM
    Mol Endocrinol; 2003 Oct; 17(10):2013-27. PubMed ID: 12855746
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mechanism of action of alpha-naphthoflavone as an Ah receptor antagonist in MCF-7 human breast cancer cells.
    Merchant M; Krishnan V; Safe S
    Toxicol Appl Pharmacol; 1993 Jun; 120(2):179-85. PubMed ID: 8390116
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.